MK-677 (Ibutamoren) vs Sermorelin
Ghrelin Mimetic · GHRH Analog
Here is how these two compounds compare, based on published research, not marketing claims.
MK-677
An oral GH secretagogue that activates the ghrelin receptor in pill form; not FDA-approved, with metabolic trade-offs.
Sermorelin
An injectable GHRH analog that mimics the body's natural growth hormone signal; historically FDA-approved as Geref.
MK-677
134 studies
24 human trials
Not FDA-Approved
Sermorelin
328 studies
20 human trials
Not FDA-Approved
What it does
MK-677
Delivers growth hormone signaling through a pill rather than an injection: the only secretagogue in this class with practical oral bioavailability. Hits the same ghrelin receptor as the injectable compounds, but in a form the gut can absorb. Clinical trials (most notably Murphy et al. and Nass et al.) documented sustained nightly growth hormone and IGF-1 elevation across the 24-hour cycle, alongside the appetite increase and changes in blood sugar handling that ultimately contributed to the failed Alzheimer's trials and the compound's research-only status today.
Sermorelin
Copies the working portion of the body's natural growth hormone signal directly, with no modifications added: just the first 29 amino acids of GHRH out of 44 in the full molecule. The original peptide in this class, and still the closest thing to what the brain actually produces. Half-life is short by design, on the order of 10 to 15 minutes, the same as native GHRH.
How it works
MK-677
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland and stimulates growth hormone release. The mechanism is functionally identical to injectable GH secretagogues like ipamorelin and GHRP-6, but the molecule is engineered for oral bioavailability. The body responds to the GH-releasing signal whether the trigger arrives by injection or by mouth. The downstream effect is increased GH followed by increased IGF-1 production from the liver.
Sermorelin
A lab-made copy of the first 29 amino acids of the body's natural growth hormone signal. It matches what the body already produces, which is why people call it the 'closest to natural' option.
How often
MK-677
Oral administration in research protocols. Published studies use daily oral dosing over periods ranging from 8 weeks to 24 weeks. MK-677 is not FDA-approved for any therapeutic indication; no approved product contains ibutamoren mesylate.
Sermorelin
In studies and historical clinical use as Geref, sermorelin was given as a daily subcutaneous injection, typically in the evening, which clinical literature describes as aligned with the body's natural overnight growth hormone pulse. The active window is brief, roughly ten minutes.
How strong
MK-677
The oral GH secretagogue. Multiple short-term controlled studies (8 weeks to 6 months) demonstrate GH and IGF-1 elevation, body composition effects, bone turnover markers, and sleep quality improvements (Copinschi 1997 showed 50% increase in stage 4 sleep duration). Reversed diet-induced catabolism in healthy volunteers (Murphy 1998). Fat-free mass gains in obese men (Svensson 1998).
Sermorelin
Mild. A modest increase over the body's natural growth hormone release, not an override.
Main tradeoff
MK-677
Oral convenience versus metabolic side effects is the core trade-off. MK-677 raises appetite (ghrelin is the hunger hormone), may elevate blood glucose and reduce insulin sensitivity, and causes water retention. The 24-week Murphy 2008 elderly hip-fracture study was discontinued due to a congestive heart failure signal in that population, the most concerning safety finding in the published literature. Whether the elderly CHF signal applies to healthy younger populations is not established. The compound has not passed Phase III trials despite decades of investigation. Compared to ipamorelin (the selective injectable alternative), MK-677 lacks the clean hormonal selectivity profile.
Sermorelin
Daily injections. Subtler effects. Some people plateau after several months.
Best for
MK-677
- Research interest in oral GH secretagogue mechanisms compared to injectable alternatives
- Research comparing sustained GH elevation (MK-677) versus pulsatile release (ipamorelin, sermorelin)
- Research contexts where the oral-versus-injectable administration question is central
Sermorelin
- Beginners to peptides
- People who want the most 'natural' approach
- Anyone prioritizing a gentle, long-term effect over peak results
How to choose
A good fit for MK-677
- Research on oral GH secretagogue mechanisms and oral bioavailability
- Research contexts where injection avoidance is the primary constraint
- Research comparing sustained GH elevation versus pulsatile release patterns
A good fit for Sermorelin
- Research on GHRH-receptor-mediated GH release using the most physiologically native analog
- Research contexts where historical FDA approval and clinical safety data carry weight
- Research populations prioritizing minimal metabolic disruption from the GH-stimulating compound
Consider both across time
MK-677 and sermorelin represent the clearest oral-versus-injectable trade-off in the GH secretagogue class. MK-677 offers pill-form convenience but activates the ghrelin pathway with appetite, glucose, and insulin sensitivity effects. Sermorelin requires daily injection but mimics the body's own GHRH signal with decades of clinical safety data and no metabolic side effects. The practical choice often comes down to whether injection avoidance or side effect minimization matters more for the research context.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Ghrelin Receptor (GHS-R1a)
- Ghrelin Receptor (GHS-R1a) activates Pituitary Somatotrophs
- Pituitary Somatotrophs connects to Growth Hormone Release
- Growth Hormone Release stimulates Liver IGF-1 Production
- Liver IGF-1 Production connects to IGF-1 Elevation; Growth Hormone Release connects to IGF-1 Elevation
- GHRH Receptor
- GHRH Receptor activates Adenylyl Cyclase
- Adenylyl Cyclase connects to cAMP Signaling
- cAMP Signaling connects to GH Transcription
- GH Transcription connects to Growth Hormone Release
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland to trigger growth hormone release; in pill form rather than injection.
Sermorelin binds the GHRH receptor on the pituitary (the body's natural 'release growth hormone' signal) and tells it to fire.
Research Evidence
Both compounds have substantial human data, though of different types. MK-677 has multiple controlled trials (8 to 24 weeks) with quantified GH/IGF-1 elevation, body composition, bone turnover, and sleep endpoints. Sermorelin has decades of clinical use data from its Geref era (FDA-approved 1997, discontinued 2008) and is one of the longest-used GH-stimulating peptides in clinical practice. Neither has published clinical outcomes data for the body composition and anti-aging endpoints that drive most current off-label use.
- 1.
If avoiding injections is essential, MK-677 is the only oral option.
- 2.
If appetite increase or glucose effects are concerns, sermorelin has a cleaner metabolic profile.
- 3.
If the longest safety track record matters most, sermorelin was once FDA-approved.
- 4.
If the most recent published human data is the priority, MK-677 has more.
Key Limitations
- •No direct head-to-head trial.
- •MK-677's metabolic side effects may limit long-term use.
- •Sermorelin's short half-life means more frequent dosing.
- •Neither has Phase III outcome data for anti-aging.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
MK-677 (Ibutamoren)
"MK-677 increased my growth hormone levels significantly"
Supported by published data
"It made me hungry all the time and I gained fat"
Supported by published data
"I use it for better sleep and recovery"
Plausible but unproven
Sermorelin
"Sermorelin is the safest way to boost growth hormone naturally"
Plausible but unproven
"It improves sleep quality dramatically"
Plausible but unproven
"It stopped working after a few months"
Plausible but unproven
Safety Comparison
Sermorelin has the longer and cleaner safety record: decades of clinical use with mild injection site reactions as the primary concern. MK-677 carries the ghrelin pathway's metabolic effects (appetite, glucose, insulin sensitivity, water retention) and the elderly hip-fracture CHF signal (Murphy 2008). The MK-677 side effect profile is more consequential for populations with metabolic risk factors. Sermorelin's side effect profile is more consequential for people who cannot tolerate daily injection.
MK-677 (Ibutamoren)
Increases appetite significantly. May elevate blood glucose and insulin. Water retention common. Long-term metabolic effects need monitoring.
Sermorelin
Previously FDA-approved (Geref). Discontinued commercially for business reasons, not safety. Well-tolerated with mild side effects.
What the Research Suggests
MK-677 is more convenient. Sermorelin is metabolically cleaner. Both raise GH effectively. The right choice depends on whether you prioritize ease of use or side effect profile.